Revvity, Inc. (NYSE:RVTY) Shares Purchased by Triodos Investment Management BV

Triodos Investment Management BV grew its position in Revvity, Inc. (NYSE:RVTY - Free Report) by 15.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,750 shares of the company's stock after acquiring an additional 3,150 shares during the quarter. Triodos Investment Management BV's holdings in Revvity were worth $2,651,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Assetmark Inc. grew its position in Revvity by 3,700.0% in the 4th quarter. Assetmark Inc. now owns 266 shares of the company's stock valued at $30,000 after acquiring an additional 259 shares during the last quarter. Continuum Advisory LLC grew its holdings in shares of Revvity by 2,972.7% in the third quarter. Continuum Advisory LLC now owns 338 shares of the company's stock worth $43,000 after purchasing an additional 327 shares during the last quarter. Millstone Evans Group LLC purchased a new position in Revvity in the 4th quarter worth about $38,000. MassMutual Private Wealth & Trust FSB lifted its holdings in Revvity by 55.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 385 shares of the company's stock valued at $43,000 after buying an additional 138 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its position in Revvity by 33.5% in the 4th quarter. EverSource Wealth Advisors LLC now owns 522 shares of the company's stock valued at $58,000 after buying an additional 131 shares during the period. Institutional investors own 86.65% of the company's stock.

Revvity Stock Down 0.7 %

Shares of RVTY stock traded down $0.71 during trading hours on Tuesday, reaching $105.10. 299,085 shares of the company's stock were exchanged, compared to its average volume of 872,358. The stock's fifty day moving average price is $114.91 and its two-hundred day moving average price is $117.04. The stock has a market cap of $12.63 billion, a PE ratio of 47.70, a PEG ratio of 3.82 and a beta of 1.06. Revvity, Inc. has a 1 year low of $97.32 and a 1 year high of $129.50. The company has a current ratio of 3.60, a quick ratio of 3.03 and a debt-to-equity ratio of 0.41.

Remove Ads

Revvity (NYSE:RVTY - Get Free Report) last issued its earnings results on Friday, January 31st. The company reported $1.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same period last year, the business posted $1.25 earnings per share. Research analysts predict that Revvity, Inc. will post 4.94 EPS for the current year.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Stockholders of record on Friday, April 18th will be paid a $0.07 dividend. The ex-dividend date of this dividend is Thursday, April 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.27%. Revvity's payout ratio is currently 12.67%.

Insider Buying and Selling

In other news, insider Tajinder S. Vohra sold 5,492 shares of the firm's stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total transaction of $641,520.52. Following the sale, the insider now owns 19,652 shares of the company's stock, valued at $2,295,550.12. This trade represents a 21.84 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Joel S. Goldberg sold 15,170 shares of Revvity stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the transaction, the insider now directly owns 33,400 shares of the company's stock, valued at approximately $4,232,782. This trade represents a 31.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.68% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Sanford C. Bernstein downgraded shares of Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 price target for the company. in a research note on Friday, January 10th. KeyCorp raised their price objective on Revvity from $132.00 to $145.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. Barclays upped their target price on Revvity from $135.00 to $140.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. Bank of America upgraded Revvity from a "neutral" rating to a "buy" rating and set a $138.00 price target on the stock in a research note on Friday, December 13th. Finally, Raymond James reaffirmed an "outperform" rating and issued a $145.00 price objective (up from $140.00) on shares of Revvity in a research note on Monday, February 3rd. Four analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $136.25.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.